After treatment, the increased IgG and CD19+ cell expression could be reduced in both respond and non-respond group regardless of patient age, while CD4+/CD8+ cell ratio could not be corrected in non-respond ITP patients. This evidence concerns the gene CD8A and autoimmune thrombocytopenic purpura.